Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Investigation Report on China's Acarbose Market, 2018-2022 -

Research and Markets
Posted on: 02 Nov 18

The "Investigation Report on China's Acarbose Market, 2018-2022" report has been added to's offering.

As a result of improved living standards, ageing population, and increasing obesity rate, the incidence of diabetes has been climbing in China. By the end of 2017, the number of diabetic patients in China exceeded 100 million, ranking first in the world and promoting the development of the diabetes drug market.

Acarbose was developed by Bayer in 1975 and first launched in Switzerland in 1986 (trade name: Glucobay). As the first FDA-approved alpha-glycosidase inhibitor in the world, it entered China in 1994 and is now recommended as a first-line drug for type 2 diabetes. Acarbose is sold far better in China than in developed countries because it reduces glucose uptake mainly by inhibiting amylase and is more suitable for Asians who eat mainly carbohydrates.

Although Acarbose has been marketed in China for more than 20 years, China's Acarbose market is dominated by Bayer, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and Sichuan Luye Baoguang Pharmaceutical Co., Ltd. because it is difficult to imitate Acarbose. In recent years, the market share of Bayer's Acarbose (trade name: Glucobay) is declining in China year by year, while the market share of domestic-made counterparts is rising. In 2017, the market size of Acarbose in China was about CNY 1.09 billion. Bayer's market share was about 66.4%, showing a continued momentum of decline.

From 2018 to 2022, the market size will continue to grow as the number of diabetic patients increases.

Topics Covered:

  • Development environment of Acarbose in China
  • Supply of and demand for Acarbose in China
  • Competition on China's Acarbose market
  • Prices of Acarbose in China
  • Forecasts on China's Acarbose market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Acarbose

1.1 Indications for Acarbose

1.2 Development of Acarbose in China

1.3 Governmental Approval of Acarbose in China

2 Sales of Acarbose in China, 2013-2017

2.1 Sales Value of Acarbose

2.2 Sales Volume of Acarbose

2.3 Sales of Acarbose by Dosage Form in China, 2013-2017

3 Analysis on Major Acarbose Manufacturers in China, 2013-2017

3.1 Analysis on Market Share of Major Acarbose Manufacturers

3.2 Bayer

3.3 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

3.4 Sichuan Luye Baoguang Pharmaceutical Co., Ltd.

4 Prices of Acarbose in China, 2017-2018

4.1 Bayer (Glucobay)

4.2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Kaboping)

4.3 Sichuan Luye Baoguang Pharmaceutical Co., Ltd. (Beixi)

5 Prospect of China's Acarbose Market, 2018-2022

5.1 Forecast on Market Size

5.2 Forecast on Market Trend

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/11/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.